

## Special Issue

# Recent Advances in Pancreatic Ductal Adenocarcinoma

### Message from the Guest Editors

We would like to invite you to submit either original research or review articles for this Special Issue on “Recent Advances in Pancreatic Ductal Adenocarcinoma (PDAC)”. The journal has an impact factor of 6.1, and you are receiving this letter as a personal invitation on behalf of one of the editors. This Special Issue will focus on the recent advances in the field of PDAC research. The topics will include but are not limited to advances in (1) pancreatic cancer surgery, especially around the equipoise of laparoscopic/robotic vs. open resections, arterial resections, and surgical management of stage 4 PDAC; (2) diagnostic and prognostic biomarkers in blood, urine, and/or tissues; (3) the pancreatic tumor microenvironment; (4) chemotherapy in neoadjuvant, adjuvant, and palliative settings; (5) radiotherapy or radio/chemotherapy; (6) postsurgical complications; (7) novel targeted therapies; (8) immunotherapy; and (9) pancreatic tumor microbiome. Thank you for your consideration. Kind regards,

---

### Guest Editors

Dr. Sumit Sahni

Dr. Anubhav Mittal

Prof. Dr. Jaswinder Samra

---

### Deadline for manuscript submissions

closed (20 January 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/47698](https://mdpi.com/si/47698)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)